0001193125-26-219678
SEC filingLosses widened in Q1 2026 as Atea ramped external spending on HCV Phase 3 clinical development and HEV preclinical activities, outpacing cost controls and lower interest income from reduced investment balances.
Atea Pharmaceuticals reported widening GAAP losses for the first quarter ended March 31, 2026, primarily due to escalated external research and development spending. Operating income deteriorated to -$48.0 million from -$39.0 million in the prior-year quarter, a 23% year-over-year increase in the loss magnitude. This net increase stemmed from higher external spend on the company's Phase 3 clinical development for HCV and preclinical activities for HEV, as contracts with CROs for studies and testing, and CMOs for clinical trial materials, intensified to advance these programs.
Net income followed suit, deepening to -$45.4 million from -$34.3 million year-over-year, or a 32.6% worsening. Diluted EPS reflected this pressure, moving to -$0.57 from -$0.40, a 42.5% decline. Interest income and other, net, contributed to the gap, decreasing due to lower investment balances, which reduced the offset to operating losses.
Cash flow from operations used -$46.4 million, up from -$30.6 million in Q1 2025, aligning with the ramp in clinical and manufacturing-related external commitments. These dynamics underscore Atea's strategy to push bemnifosbuvir and ruzasvir toward potential commercialization, including manufacturing launch supply, while advancing AT-587 for HEV treatment. Management anticipates R&D expenses will fluctuate quarter-to-quarter as the Phase 3 HCV program nears completion.